NZ Colorectal Oncology Research Review Issue 35

In this issue:
  -  Acquired genomic alterations on first-line chemotherapy with cetuximab
  -  Global burden of CRC in 2020 and 2040
  -  Galunisertib + neoadjuvant chemoradiotherapy for locally advanced rectal cancer
  -  FOLFOXIRI + bevacizumab and atezolizumab for metastatic CRC
  -  Modified FOLFOXIRI + panitumumab for metastatic CRC
  -  Fluoropyrimidine + bevacizumab with irinotecan escalation for metastatic CRC
  -  FOLFOX + panitumumab after resection of CRC liver metastases
  -  Apatinib-chemotherapy combinations for advanced CRC
  -  Personalized total neoadjuvant therapy for advanced rectal cancer
  -  FOLFIRI + cetuximab vs bevacizumab for RAS wild-type metastatic CRC

Please login below to download this issue (PDF)

Subscribe